ROC curve performance of the 12-biomarker naïve Bayes NSCLC classifier by study site.

<p>ROC curve performance of the 12-biomarker naïve Bayes NSCLC classifier by study site.</p

Performance of classifier in demographic subsets.

<p>Performance of classifier in demographic subsets.</p

Heat map shows the magnitude of difference for each protein measured (columns) between subject populations for the comparison of NSCLC to controls (top row) and comparisons of cases or controls between study sites (bottom row).

<p>Top row: KS distances for NSCLC versus control distributions. Bottom row: mean KS distances for all 12 pair-wise comparisons, between the four sites, of case and control samples analyzed separately. Proteins were ordered by subtracting the NSCLC KS distance from the mean site KS distance. This revealed groups of NSCLC biomarkers (top right) contrasting with preanalytical markers (bottom left).</p

Classifier specificity by level of airflow obstruction.

§<p>Spirometric classification of airflow obstruction based on GOLD staging <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015003#pone.0015003-GOLD1" target="_blank">[60]</a>.</p

Performance of Bayesian Classifier to distinguish NSCLC cases from controls.

<p>Performance of Bayesian Classifier to distinguish NSCLC cases from controls.</p

Potential NSCLC biomarkers^§.

§<p>Measure of the relative importance of potential biomarkers selected with KS distance (KS), KS FDR-corrected q-value (q-value), frequency for naïve Bayes (NB Freq),</p

Clinical characteristics of NSCLC case and control sets for training and verification.

§<p>For continuous data the differences were tested using t-tests. For categorical data significant differences were tested using the Pearson Chi-Squared Test for independence.</p>‡<p>Pack-years: product of the self reported number of packs of cigarettes smoked per day and the number of years of smoking.</p

Clinical characteristics of NSCLC cases in the training and verification sets.

§<p>Clinical staging for 17 Stage I, 5 Stage II and 29 Stage III cases, NOS not otherwise specified.</p

Twelve biomarker classifier proteins^§.

§<p>Up or down regulation in NSCLC cases relative to controls.</p

ROC curve for 12-biomarker naïve Bayes classifier.

<p>ROC curve for 12-biomarker naïve Bayes classifier.</p